These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 11907740)

  • 21. Drug therapy during percutaneous coronary interventions in stable and unstable coronary artery disease: the Italian Drug Evaluation in Angioplasty (IDEA) study.
    Savonitto S; Ambrosini V; Marzocchi A; Tolaro S; Petronio AS; Galassi AR; Bongo AS; Gaglione A; Bolognese L; ;
    Ital Heart J; 2005 Feb; 6(2):106-18. PubMed ID: 15819503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of platelet glycoprotein IIb/IIIa inhibitors in rescue percutaneous coronary interventions.
    Petronio AS; De Carlo M; Rossini R; Amoroso G; Limbruno U; Ciabatti N; Palagi C; Caravelli P; Mariani M
    Ital Heart J; 2004 Feb; 5(2):114-9. PubMed ID: 15086140
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
    Mukherjee D; Mahaffey KW; Moliterno DJ; Harrington RA; Yadav JS; Pieper KS; Gallup D; Dyke C; Roe MT; Berdan L; Lauer MS; Mänttäri M; White HD; Califf RM; Topol EJ
    Am Heart J; 2002 Dec; 144(6):995-1002. PubMed ID: 12486423
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacodynamics and pharmacokinetics of the platelet GPIIb/IIIa inhibitor tirofiban in patients undergoing percutaneous coronary intervention: implications for adjustment of tirofiban and clopidogrel dosage.
    Kimmelstiel C; Badar J; Covic L; Waxman S; Weintraub A; Jacques S; Kuliopulos A
    Thromb Res; 2005; 116(1):55-66. PubMed ID: 15850609
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Beyond aspirin: how glycoprotein inhibitors ease acute coronary syndromes.
    MacCallum EM; Hanlon SJ; Byrne KH
    Dimens Crit Care Nurs; 2000; 19(3):14-9. PubMed ID: 11998001
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is transport with platelet GP IIb/IIIa inhibition for primary percutaneous coronary intervention more efficient than on-site thrombolysis in patients with STEMI admitted to community hospitals? Randomised study. Early results.
    Dobrzycki S; Mezyński G; Kralisz P; Prokopczuk P; Nowak K; Kochman W; Zuk J; Bachórzewska-Gajewska H; Sawicki Z; Poniatowski B; Korecki J; Musiał WJ
    Kardiol Pol; 2006 Aug; 64(8):793-9; discussion 800-1. PubMed ID: 16981054
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjunctive pharmacotherapy before percutaneous coronary intervention in non-ST-elevation acute coronary syndromes: the role of modulating inflammation.
    Kereiakes DJ
    Circulation; 2003 Oct; 108(16 Suppl 1):III22-7. PubMed ID: 14605016
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Inhibitors of the platelet's receptor GPIIb/IIIA. Progress in the treatment of acute myocardial ischemia and future trends].
    Cacciapuoti F
    Minerva Cardioangiol; 2001 Dec; 49(6):413-6. PubMed ID: 11733737
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IIb/IIIa or not IIb/IIIa? That is the question.
    Redwood S
    Int J Clin Pract; 1999 Dec; 53(8):577. PubMed ID: 10692749
    [No Abstract]   [Full Text] [Related]  

  • 30. Acute coronary syndromes: optimizing the therapeutic options.
    Gershlick AH
    Eur Heart J; 2002 Feb; 23(3):194-7. PubMed ID: 11792132
    [No Abstract]   [Full Text] [Related]  

  • 31. Use of concomitant glycoprotein IIb/IIIa inhibitors with catheter-directed peripheral arterial thrombolysis.
    Ouriel K
    J Vasc Interv Radiol; 2004 Jun; 15(6):543-6. PubMed ID: 15178713
    [No Abstract]   [Full Text] [Related]  

  • 32. Basic and clinical aspects of platelet integrin alphaIIbbeta3 receptor antagonists in acute coronary syndromes.
    Goudevenos JA; Tselepis AD
    Curr Opin Investig Drugs; 2001 Feb; 2(2):244-9. PubMed ID: 11816838
    [No Abstract]   [Full Text] [Related]  

  • 33. NICE appraisals and cardiology: glycoprotein IIb/IIIa inhibitors and acute coronary syndromes.
    Hyde T; Knight C
    Hosp Med; 2003 Nov; 64(11):638-9. PubMed ID: 14671871
    [No Abstract]   [Full Text] [Related]  

  • 34. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Harding SA; Boon NA; Flapan AD
    Lancet; 2002 Jul; 360(9328):256-7. PubMed ID: 12133681
    [No Abstract]   [Full Text] [Related]  

  • 35. [Treatment of patients with acute coronary syndrome in the United States with glycoprotein IIb/IIIa inhibitors. Data provided by the PURSUIT study].
    Galvani M
    Ital Heart J Suppl; 2000 Dec; 1(12):1650-1. PubMed ID: 11221597
    [No Abstract]   [Full Text] [Related]  

  • 36. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Boersma E; Harrington RA; Moliterno DJ; White H; Simoons ML
    Lancet; 2002 Jul; 360(9329):342-3. PubMed ID: 12147403
    [No Abstract]   [Full Text] [Related]  

  • 37. Platelet glycoprotein IIb/IIIa receptor inhibitors in coronary artery disease.
    Cohen M
    Ann Intern Med; 1996 May; 124(9):843-4. PubMed ID: 8610955
    [No Abstract]   [Full Text] [Related]  

  • 38. Acute coronary syndrome.
    Khavandi A; Walker PR
    BMJ; 2007 Mar; 334(7595):647-8. PubMed ID: 17395906
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessing the optimal level of platelet inhibition with GPIIb/IIIa inhibitors in patients undergoing coronary intervention. Rationale and design of the GOLD study.
    Steinhubl SR
    J Thromb Thrombolysis; 2000 Apr; 9(3):199-205. PubMed ID: 10728017
    [No Abstract]   [Full Text] [Related]  

  • 40. Glycoprotein IIb/IIIa inhibitor therapy and outcomes after percutaneous coronary intervention.
    Tepper RI; Simonian N
    Am J Cardiol; 2003 Sep; 92(6):771-2. PubMed ID: 12972136
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.